This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
11
KVD900 Tablet 600 mg (2 x 300 mg)
KVD900 Tablet 300 mg
Pharmacokinetics - Cmax
Time frame: Up to 6 hours after IMP administration
Pharmacokinetics - Tmax
Time frame: Up to 6 hours after IMP administration
Pharmacokinetics - AUC
Time frame: Up to 6 hours after IMP administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
KalVista Investigative Site
Scottsdale, Arizona, United States
KalVista Investigative Site
Little Rock, Arkansas, United States
KalVista Investigative Site
San Diego, California, United States
KalVista Investigative Site
San Diego, California, United States
KalVista Investigative Site
Santa Monica, California, United States
KalVista Investigative Site
Centennial, Colorado, United States
KalVista Investigative Site
Colorado Springs, Colorado, United States
KalVista Investigative Site
Evansville, Indiana, United States
KalVista Investigative Site
Overland Park, Kansas, United States
KalVista Investigative Site
Louisville, Kentucky, United States
...and 51 more locations